OncoMatch/Clinical Trials/NCT06819007
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Is NCT06819007 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Trastuzumab Deruxtecan and Bevacizumab for ovarian cancer.
Treatment: Trastuzumab Deruxtecan · Bevacizumab — This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 3+/2+/1+ (ASCO-CAP gastric cancer IHC scoring 2016))
HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+/2+/1+) guidelines by prospective central testing
Excluded: BRCA1 deleterious alteration
Has a known or suspected deleterious BRCA alteration as per local test that makes the patient eligible for PARP inhibitor
Excluded: BRCA2 deleterious alteration
Has a known or suspected deleterious BRCA alteration as per local test that makes the patient eligible for PARP inhibitor
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
Grade: high-grade
newly diagnosed FIGO Stage III or IV
Prior therapy
Must have received: bevacizumab in combination with frontline platinum-based chemotherapy (bevacizumab, platinum-based chemotherapy) — frontline
Has received up to 6 cycles of standard of care bevacizumab in combination with frontline platinum-based chemotherapy as per approved indication and clinical guidelines and is eligible to continue single agent bevacizumab maintenance
Cannot have received: PARP inhibitor
Participant to receive PARP inhibitor as maintenance per standard of care and investigator discretion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Scripps Clinic · La Jolla, California
- Broward Health Medical Center · Fort Lauderdale, Florida
- Jupiter Medical Center · Jupiter, Florida
- Mount Sinai Medical Center · Miami Beach, Florida
- AdventHealth Cancer Institute · Orlando, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify